Search

Brinzolamide

[A2049,A2051] Although systemic anti-carbonic anhydrase (CA) therapy has been used for almost 50 years with varying degrees of success, systemic administration results in an increase in incidences of adverse

Batroxobin

Batroxobin is a defibrinogenating hemostatic agent derived from the venom of a pit viper, Bothrops atrox moojeni. In addition to batroxobin, the venom of Bothrops atrox has a composition of 10.2% neutral carbohydrate. Batroxobin is a ser...

Itolizumab

Itolizumab is under investigation in clinical trial NCT04605926 (A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19).

Mitoquinone

Mitochondrial dysfunction also has been shown to represent an early critical event in the pathogenesis of the sporadic form of Parkinson's disease. … Clinical studies by the Parkinson's Study Group show that very high doses of an antioxidant called Coenzyme Q (which Mitoquinone effectively targets into mitochondria) appear to slow the progression of

Nizubaglustat

Nizubaglustat has a monoisotopic molecular weight of 433.23 Da.

Vicadrostat

Vicadrostat has a monoisotopic molecular weight of 317.06 Da.

Farnesol

It is an intermediate step in the biological synthesis of cholesterol from mevalonic acid in vertebrates. It has a delicate odor and is used in perfumery.

Fenoxaprop-ethyl

Fenoxaprop-ethyl (organic nitrate combined with L-arginine), is an oral proprietary nitrate therapeutic shown to induce coronary vasodilation while overcoming the significant problem of drug tolerance.

ICA-105665

ICA-105665 is a novel small molecule compound for the treatment of epilepsy. It is a novel opener of the KCNQ ion channel which in preclinical studies has demonstrated a broad spectrum of activity in models of epilepsy. In addition, ICA-...

Butropium